CN1376497A - Qizhen capsule and its preparing process - Google Patents
Qizhen capsule and its preparing process Download PDFInfo
- Publication number
- CN1376497A CN1376497A CN 02110948 CN02110948A CN1376497A CN 1376497 A CN1376497 A CN 1376497A CN 02110948 CN02110948 CN 02110948 CN 02110948 A CN02110948 A CN 02110948A CN 1376497 A CN1376497 A CN 1376497A
- Authority
- CN
- China
- Prior art keywords
- margarita
- precious
- powder
- ethanol
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title description 4
- 230000008569 process Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 24
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 19
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 19
- 239000000463 material Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- 239000000843 powder Substances 0.000 claims description 39
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 31
- 244000293323 Cosmos caudatus Species 0.000 claims description 31
- 239000000706 filtrate Substances 0.000 claims description 24
- 239000009636 Huang Qi Substances 0.000 claims description 23
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 22
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims description 22
- 235000021286 stilbenes Nutrition 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 238000005325 percolation Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 102000011759 adducin Human genes 0.000 claims description 4
- 108010076723 adducin Proteins 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 6
- 206010017758 gastric cancer Diseases 0.000 abstract description 6
- 201000011549 stomach cancer Diseases 0.000 abstract description 6
- 206010006187 Breast cancer Diseases 0.000 abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 2
- 208000020816 lung neoplasm Diseases 0.000 abstract description 2
- 241000334160 Isatis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 238000002512 chemotherapy Methods 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- 238000006424 Flood reaction Methods 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 206010043089 tachypnoea Diseases 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 210000003459 common hepatic duct Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- -1 lipid free radical Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine "Qizhen capsule" for treating tumor is prepared from 5 Chinese-medicinal materials including pearl, astragalus root, notoginseng, isatis leaf, etc. Its advantages are sure curative effect, no toxic by-effect, and low cost. It can be used for auxiliary therapy after chemicotherapy of lung cancer, breast cancer and stomach cancer.
Description
Technical field
The present invention relates to a kind of adjuvant drug for the treatment of tumor.
Background technology
Malignant tumor is commonly encountered diseases and a frequently-occurring disease clinically, and annual about more than 600 ten thousand people in the whole world die from malignant tumor, especially in, the old people, owing to have a delicate constitution, negative and positive losss, its sickness rate is higher than general crowd, during many case-findings to middle and advanced stage, often healthy energy consume, knot in the stagnant heat, it is thin to cause body to be won, and the state of an illness increases the weight of, therefore, how to prevent and treat malignant tumor effectively and become the research topic that countries in the world are more and more paid close attention to.The Western medicine that the chemotherapy of the treatment malignant tumor of supplying on the current medical market is used, though certain effect is arranged, toxic and side effects is big, easily causes leukocyte to reduce, resistance descends, and makes that the patient feels sick, anorexia, diarrhoea, alopecia, very painful, and price is more expensive, makes the patient be difficult to economically bear.Also have the various Chinese medicinal capsules for the treatment of simultaneously in the market with chemotherapy, though relatively cheap on the price, find that clinically effect is not very desirable.
Summary of the invention
Technical problem to be solved by this invention provide a kind of can leukocyte increasing, enhancing immunity, have no side effect and the precious capsule of stilbene of low-cost treatment tumor and preparation method thereof.
The present invention solves the problems of the technologies described above the technical scheme that is adopted: the precious capsule of stilbene of the present invention, made by Margarita, the Radix Astragali, Radix Notoginseng, Folium Isatidis and Rhizoma Paridis, the percentage by weight of each material component is: Margarita 9.2%-13.8%, Radix Astragali 39%6-57%, Radix Notoginseng 7.2%-10.8%, Folium Isatidis 14.4%-21.6%, Rhizoma Paridis 10.8%-16.2%.
Preparation method of the present invention is: (1) decocts with water secondary with the Radix Astragali, 1.9-2.1 hour for the first time, 0.9-1.1 hour for the second time, collecting decoction filtered, filtrate is evaporated to relative density 1.08-1.10 under 48 ℃-52 ℃, add ethanol and make the alcohol amount of containing be 65%-75%, leave standstill, filter, filtrate is reclaimed, add the water dissolution that 3.6-4.4 doubly measures in precipitate after, filter, filtrate adds ethanol to be made and contains the alcohol amount and be 70%-80%, leave standstill, filter, reclaim filtrate, precipitate dried under reduced pressure, dry extract, pulverize again, sieving obtains 80-120 purpose fine drug powder; (2) Margarita is cleaned earlier, eluriates, drains after, then with soak with ethanol, pulverize, be screened into middle powder, again water fly to pulverize, dry, be screened into fine powder; (3) with Radix Notoginseng, Folium Isatidis and Rhizoma Paridis through pulverizing, making solvent with ethanol after moistening, flood after 23.5-24.5 hour percolation, collect percolate, percolate is added the above-mentioned fine powder of Margarita, the mixing of making after being evaporated to relative density 1.28-1.30 under 38 ℃-42 ℃, get extractum, drying under reduced pressure gets dry extract again, gets 80-120 purpose fine drug powder after pulverizing, sieving, add the 80-120 order fine drug powder that the Radix Astragali makes again, mixing incapsulates, promptly.
The invention has the advantages that: because the raw material resources among the present invention is abundant, mature production technology, so easily realize industrialization production, product price is cheap, patient in hospital is acceptant; Also have no side effect, can long-term safety use.Through the 5 tame II of hospital clinical trial phases above the provincial level such as Guang-amen Hospital, China Traditional Chinese Medicine Instl, Hunan Province tumour hospital, Beijing China-Japan Friendship Hospital, Jiangxi Prov. Tumour Hospital, Zhejiang Prov. Hospital of Traditional Chinese Medicine, cancer patient's 307 examples such as treatment pulmonary carcinoma, breast carcinoma, gastric cancer, total effective rate is 86.32%..Confirmation is analysed in credit by statistics, and the precious capsule of stilbene and chemotherapy drug combination have the toxic action of alleviating to the blood stasis due to qi deficiency stasis of blood resistance heat-transformation card tumor patient of holding concurrently, and can improve the blood stasis due to qi deficiency stasis of blood resistance heat-transformation syndrome of holding concurrently, and improves immunologic function and life quality, and weight increase is protected leukocyte; Safety has no side effect.The precious capsule of stilbene is applicable to that hold concurrently stasis of blood resistance heat-transformation card pulmonary carcinoma, breast carcinoma and gastric cancer of blood stasis due to qi deficiency is main various patients, is new Chinese medicine safely and effectively.
Description of drawings
Fig. 1 is a process flow diagram of the present invention.
The specific embodiment
The pharmacology principle of each composition among the present invention: contain 17 seed amino acids in (1) Margarita, the trace element of 32 kinds of needed by human body, wherein contained biologically actived calcium reaches more than 60%, with the intravital organizational building of participant, improves body immunity, strengthens phagocytic activity.Show after deliberation: the intravital free radical of people, all unstable as oxygen-derived free radicals and lipid free radical, active high, be to cause that gene mutation, teratogenesis are carcinogenic, cause one of old and feeble reason, contained trace element-selenium is a kind of antioxidant preferably in the Margarita, helps to remove the intravital various free radicals of people.(2) Radix Astragali contains astragalus polysaccharides, aminoacid and trace element: potassium, sodium, calcium, magnesium, ferrum, zinc and selenium etc. have the promoting the circulation of QI yang invigorating, benefit is defended effects such as consolidating superficial resistance, antitoxin granulation promoting, evacuation of pus.It is weary to control the deficiency of vital energy, lack of appetite, sinking of QI of middle-JIAO, exterior deficiency spontaneous perspiration, the swollen difficult stain of pain, blood deficiency and yellow complexion, interior-heat human body diseases such as quench one's thirst; Diseases such as (3) Radix Notoginseng contains ginsenoside and flavonoid glycoside etc., has the dissipating blood stasis hemostasis, and the effect of subduing swelling and relieving pain (4) Folium Isatidis contains the indigo glycoside, and effects such as tool heat-clearing and toxic substances removing, removing heat from blood are controlled pathogenic warmth to join the army, and pain is swollen.(5) Rhizoma Paridis contains intact glycoside of multiple Rhizoma Paridis and several amino acids, has heat reliving and toxin-eliminating, reducing swelling and alleviating pain, and the effect of cool liver arresting convulsion can be treated pain and be swollen.Five kinds of compositions are played altogether, have the effect of benefiting qi and removing blood stasis, heat-clearing and toxic substances removing.
Below in conjunction with embodiment the present invention is described in further detail.
Embodiment 1: select the optimum feed stock weight percentages for use: Margarita 11.5%, the Radix Astragali 48%, Radix Notoginseng 9%, Folium Isatidis 18%, Rhizoma Paridis 13.5%, for example select Margarita 180 grams, the Radix Astragali 750 grams, Radix Notoginseng 140 grams, Folium Isatidis 280 grams, Rhizoma Paridis 210 grams for use.
Its preparation method is: (1) decocts with water secondary with the Radix Astragali, and 2 hours for the first time, 1 hour for the second time, collecting decoction filters, and filtrate is evaporated to relative density 1.08-1.10 under 50 ℃, add 95% ethanol and make that to contain alcohol amount be 70%, leave standstill, filter, filtrate is reclaimed, in precipitate, add 4 times of water gagings dissolvings after, filter, filtrate adds 95% ethanol makes that to contain alcohol amount be 75%, leaves standstill, and filters, reclaim filtrate,, be ground into 100 purpose fine drug powders again getting dry extract after the precipitate dried under reduced pressure; (2) Margarita is cleaned earlier, eluriates, drains after, then with 75% soak with ethanol, pulverize, be screened into powder in 70 purposes, again water fly to pulverize, dry, sieve, sterilize, weigh, the qualified back of quality inspection becomes the fine powder of 120 purposes; (3) with Radix Notoginseng, Folium Isatidis and the Rhizoma Paridis done through pulverizing, it is moistening to spray 65% ethanol, evenly pack in the columniform percolator, reuse 65% alcohol is made solvent, flood after 24 hours, percolation is collected percolate, and percolate is added above-mentioned 120 purpose Margarita powder after being evaporated to relative density 1.28-1.30 under 40 ℃, get extractum behind the mixing, vacuum drying obtains dry extract then, pulverize again, sieve 100 purpose fine drug powders, add the 100 purpose fine drug powders that the Radix Astragali makes then, mixing, incapsulate, make 1000, promptly.
The technical process of its preparation as shown in Figure 1.
Embodiment 2: the percentage by weight of selecting each material component for use: Margarita 9.2%, the Radix Astragali 57%, Radix Notoginseng 7.2%, Folium Isatidis 14.4%, Rhizoma Paridis 12.2%, for example select Margarita 144 grams, the Radix Astragali 900 grams, Radix Notoginseng 112 grams, Folium Isatidis 224 grams, Rhizoma Paridis 180 grams for use.
Its preparation method and roughly the same above-mentioned: (1) decocts with water secondary with the Radix Astragali, 2.1 hours for the first time, 0.9 hour for the second time, collecting decoction filters, and filtrate is evaporated to relative density 1.08-1.10 under 48 ℃, add 95% ethanol and make that to contain alcohol amount be 65%, leave standstill, filter, filtrate is reclaimed, after in precipitate, adding 3.6 times of water gaging dissolvings, filter, filtrate adds 95% ethanol makes that to contain the alcohol amount be 70%, leaves standstill, filter, reclaim filtrate,, be ground into 80 purpose fine drug powders again getting dry extract after the precipitate dried under reduced pressure; (2) situation of the manufacturing process of Margarita and the foregoing description roughly the same, after difference is that Margarita cleans, eluriates, drains, with 65% soak with ethanol, pulverize, be screened into powder in 50 purposes, again water fly to pulverize, dry, sieve, sterilize, weigh, the qualified back of quality inspection becomes the fine powder of 100 purposes; (3) with Radix Notoginseng, Folium Isatidis and the Rhizoma Paridis done through pulverizing, it is moistening to spray 60% ethanol, in the percolator of evenly packing into, reuse 60% ethanol is made solvent, floods after 23.5 hours percolation, collect percolate, percolate is evaporated to relative density 1.28-1.30 under 38 ℃; Add above-mentioned 100 purpose Margarita powder, behind the mixing extractum, vacuum drying obtains dry extract then, pulverize again, sieve 80 purpose fine drug powders, add the 80 purpose fine drug powders that the Radix Astragali makes then, mixing incapsulates, and makes 1000, promptly.
Identical among its production technology and the embodiment 1.
Embodiment 3: select for use the percentage by weight of each material component to be: Margarita 13.8%, the Radix Astragali 41.2%, Radix Notoginseng 7.2%, Folium Isatidis 21.6%, Rhizoma Paridis 16.2%, for example select Margarita 198 grams, the Radix Astragali 699 grams, Radix Notoginseng 124 grams, Folium Isatidis 308 grams, Rhizoma Paridis 231 grams for use.
Its preparation method is: (1) decocts with water secondary with the Radix Astragali, and 1.9 hours for the first time, 1.1 hours for the second time, collecting decoction filters, and filtrate is evaporated to relative density 1.08-1.1 under 52 ℃, add 95% ethanol and make that to contain alcohol amount be 75%, leave standstill, filter, filtrate is reclaimed, in precipitate, add 4.4 times of water gagings dissolvings after, filter, filtrate adds 95% ethanol makes that to contain alcohol amount be 80%, leaves standstill, and filters, reclaim filtrate,, be ground into 120 purpose fine drug powders again getting dry extract after the precipitate dried under reduced pressure; (2) situation of the manufacturing process of Margarita and the foregoing description roughly the same, after difference is that Margarita cleans, eluriates, drains, with 80% soak with ethanol, pulverize, be screened into powder in 90 purposes, again water fly to pulverize, dry, sieve, sterilize, weigh, the qualified back of quality inspection becomes the fine powder of 140 purposes; (3) with Radix Notoginseng, Folium Isatidis and the Rhizoma Paridis done through pulverizing, it is moistening to spray 70% ethanol, in the columniform percolator of evenly packing into, reuse 70% ethanol is made solvent, floods after 24.5 hours percolation, collect percolate, percolate is evaporated to relative density 1.28-1.30 under 42 ℃; Add above-mentioned 140 purpose Margarita powder, behind the mixing extractum, vacuum drying obtains dry extract then, pulverize again, sieve 120 purpose fine drug powders, add the 120 purpose fine drug powders that the Radix Astragali makes then, mixing incapsulates, and makes 1000, promptly.Identical among its production technology and the embodiment 1.
With the precious capsule of stilbene that said method makes, its main performance index is: every contains Folium Isatidis with indirubin (C
16H
10N
2O
2) meter＞12 μ g, Margarita is in calcium (Ca)＞50mg.
Function cures mainly and usage and dosage: benefiting qi and removing blood stasis, heat-clearing and toxic substances removing is used for the auxiliary treatment of tumor patient chemotherapy such as pulmonary carcinoma, breast carcinoma, gastric cancer.Oral, each 5,3 times on the one, six weeks were a course of treatment, used simultaneously with chemotherapy.
Pharmacological action: be diluted to desired concn with 0.5%CMC-Na, the dosage setting with the precious capsule of stilbene of the present invention: mice po4.5,1.5 and ip 1.5,0.75g/kg by Shanghai Institute of Pharmaceutical Industry; Rat po3.0,1.5 and ip 1.5,0.75g/kg only is 0.5ml/ to the volume injected of large and small Mus.Oral or intraperitoneal administration, once a day, continuous ten days.Pharmacological testing shows: this product can promote the phagocytic function of macrophage, improve the NK cell and the lymphocytic activity of T of tumor-bearing mice, the suppression ratio of rat w256 carcinosarcoma, Mice Bearing Lewis Lung Cancer and S180 sarcoma, human tumor QGY hepatocarcinoma is reached more than 40%; Merge using with cyclophosphamide has potentiation trend, and the leucocytes reduction of caused by cyclophosphamide immunocompromised mice is had the certain protection effect.
The precious capsule of stilbene of the present invention is ratified by National Drug Administration, the II phase clinical research of carrying out, observed and belonged to traditional Chinese medical science blood stasis due to qi deficiency pulmonary carcinoma, gastric cancer, breast carcinoma totally 472 examples of stasis of blood resistance heat-transformation card of holding concurrently, test group 307 examples wherein, matched group 165 examples, chemotherapy is added the precious Capsules group of stilbene be called test group, chemotherapy adds ZHENQI FUZHENG JIAONANG (commercially available) group and is called matched group, and existing contrast is summarized as follows:
The comparison that treatment back cancer changes
| Group | ????N | ??CR | ???PR | ???MR | ???SD | ??PD | Effective percentage | The sum of ranks inspection | |
| Pulmonary carcinoma | Test group | ???167 | ??7 | ???26 | ???37 | ???91 | ??6 | ??19.8％ | ??P＞0.05 |
| Matched group | ???88 | ???11 | ???6 | ???64 | ??7 | ??12.5％ | |||
The overall comparison that changes of the two groups of NK cells in treatment back
| Grouping | ????N | Raise | Stable | Descend | The raising rate |
| Test group | ???253 | ????124 | ????112 | ????17 | ????49.01 |
| Matched group | ???139 | ????32 | ????63 | ????44 | ????12.02 |
The blood stasis due to qi deficiency comparison of stasis of blood resistance heat-transformation doing well,improving general curative effect of holding concurrently
| Syndrome | Test group (N=307) | Matched group (N=165) | ||||
| Before the treatment | After the treatment | Effective percentage % | Before the treatment | After the treatment | Effective percentage % | |
| Spiritlessness and weakness | ????275 | ????61 | ????77.5 | ??162 | ????92 | ????43.2 |
| Sweating is breathed hard | ????245 | ????86 | ????64.9 | ??141 | ????90 | ????36.2 |
| It is unable to cough | ????195 | ????70 | ????64.1 | ??107 | ????68 | ????36.4 |
| Dry mouth and throat | ????105 | ????28 | ????73.3 | ??47 | ????25 | ????46.8 |
| Cardiopalmus is vexed | ????118 | ????33 | ????72.0 | ??41 | ????32 | ????22.0 |
| Chest pain | ????147 | ????49 | ????66.7 | ??81 | ????31 | ????61.7 |
| Cough with blood-flecked phlegm | ????105 | ????17 | ????83.8 | ??26 | ????18 | ????30.1 |
Two groups of treatment back CD
4/ CD
8The overall comparison that changes of ratio
| Group | ????N | Improve | Stable | Reduce | Raising rate % |
| Test group | ???253 | ????111 | ????128 | ????14 | ????43.87 |
| Matched group | ???139 | ????35 | ????80 | ????24 | ????25.18 |
Comparison (thousand/mm that leukocyte changes before and after the treatment
3)
Model case: case one:
| Group | ??N | ????～4.0 | ????～3.0 | ????～2.0 | ????～1.0 | ????～1.0 | |||||
| Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Test group | ??307 | ??307 | ??291 | ???/ | ???16 | ||||||
| Matched group | ??165 | ??165 | ??150 | ???/ | ???10 | ????/ | ???5 | ||||
Patient Yin * *, the man, 63 years old, patient's identification number was 73492, diagnosis: left lung non-small cell carcinoma, twin-lock bone superior gluteal lymph node shifts, cell student number: 99163.Uncomfortable in chest before the treatment, breathe hard, cough, expectoration, poor physical capacity, blood routine examination is normal, immunologic function detects: CD
350%, CD
432%, CD
4/ CD
81.2, NK cytoactive 6%.Therapeutic Method: chemotherapy (carboplatin+sufficient leaf glycoside/cyclophosphamide+epirubicin+vincristine, both alternately) add the precious capsule of stilbene, the precious capsular usage of stilbene: each 5, every day 3 times, serve on 42 days.Blood picture is always in normal range in therapeutic process, chemotherapy can be as scheduled according to plan dosage finish, treat 1 all after date check T cell subsets, CD
361%, CD
439%, CD
4/ CD
81.4, NK cytoactive 9%, immunologic function obviously improves, and patient is uncomfortable in chest, breathe hard etc., and disease alleviates, twin-lock bone superior gluteal lymph node disappears, check lung CT, primary lesion dwindles more than 90%, patient is disease free survival still now.Case two:
The king * *, man, 49 years old, patient's identification number 87917.1999 November 3 days of patient, capable radical operation for carcinoma of stomach was visited in the art and lump is positioned at body of stomach, lesser gastric curvature rear flank wall, the also visible serous coat of antetheca is invaded, doing the left artery side lays one's hand on and enlarged lymph node, the postoperative pathological replacement is: the poorly differentiated adenocarcinoma cancer, soak into the coat of the stomach holostrome, and lymph node of lesser curvature of stomach 2/3 is seen cancerometastasis, pathological number is 129660, postoperative changes department of Chinese medicine treatment on November 24th, 99, and disease is seen upper right abdomen dull pain, spiritlessness and weakness when transferring from one department to another, appetite reduces, abdominal distention and pain appears in postoperative patient in January, not bowel movement, and plain abdominal radiograph is considered intestinal obstruction, CT examination when transferring from one department to another: postoperative gastric cancer changes, residual coat of the stomach is not thick, gallbladder inflammation, and common hepatic duct is expansion slightly, CT number is 44078, T cell subsets CD
348%, CD
429%, CD
4/ CD
80.9, NK cytoactive 8%.Take each 5 of the precious capsule of stilbene, add the CF scheme 3 times every day, three cycles of chemotherapy, the upper right abdomen dull pain of treatment back patient, abdominal distention are alleviated substantially, and defecation is unobstructed, and spirit takes a turn for the better, the more preceding increase of dietary amount, the check B ultrasonic shows: behind liver, gallbladder, spleen, the abdomen pancreas, two kidney no abnormality seen, B ultrasonic number is 9910277, T cell subsets CD
360%, CD
436%, CD
4/ CD
81.35, NK cytoactive 11%, routine blood test WBC 4.98 * 10
9/ L, Hb 110g/L, PLT 189 * 10
9/ L, hepatic and renal function is normal.Case three:
The land * *, woman 42 years old, patient's identification number 87483, the patient is a primary bronchogenic carcinoma of lung through a CT and a sight glass pathological diagnosis, right median type T
2N
2M
1The IV phase, two lungs shifted senior middle school's differentiation adenocarcinoma, were in hospital symptoms including cough, sputum mixed with blood, movable back tachypnea, T cell subsets CD on February 29th, 2000
349%, CD
427%, CD
4/ CD
80.7, NK cytoactive 7%, CT shows: the about 6.2 * 6.2cm of the other soft mass's maximum diameter of right upper lung mediastinum
2, multiple cellular metastatic tumor in the bilateral lung is taken each 4 of the precious capsule of stilbene, adds taxol+1 cycle of cisplatin scheme chemotherapy every day 3 times, finishes the back cough course of treatment and alleviates, and sputum mixed with blood disappears, and tachypnea is alleviated, treatment back check T cell subsets CD
362%, CD
438%, CD
4/ CD
81.37, NK cytoactive 12%, CT shows: right upper lung piece shadow before dwindles, existing maximum diameter is about 4.5 * 4.5cm
2, the more preceding no significant change of the multiple cellular metastatic tumor of two lungs, CT number is 44687, routine blood test: WBC6.08 * 10
9/ L Hb 110g/L, PLT332 * 10
9/ L, hepatic and renal function is normal.
Claims (9)
1. the precious capsule of a stilbene, make by Margarita, the Radix Astragali, Radix Notoginseng, Folium Isatidis and Rhizoma Paridis, it is characterized in that the percentage by weight of each material component is: Margarita 9.2%-13.8%, Radix Astragali 39%-57%, Radix Notoginseng 7.2%-10.8%, Folium Isatidis 14.4%-21.6%, Rhizoma Paridis 10.8%-16.2%.
2. the precious capsule of stilbene according to claim 1 is characterized in that the percentage by weight of each material component is: Margarita 11.5%, the Radix Astragali 48%, Radix Notoginseng 9%, Folium Isatidis 18%, Rhizoma Paridis 13.5%.
3. the precious capsular preparation method of a stilbene, it is characterized in that: (1) decocts with water secondary with the Radix Astragali, and 1.9-2.1 hour for the first time, 0.9-1.1 hour for the second time, collecting decoction, filter, filtrate is evaporated to relative density 1.08-1.10 under 48 ℃-52 ℃, adds ethanol and makes it contain the alcohol amount to be 65%-75%, leave standstill, filter, filtrate reclaimed, in precipitate, add 3.6-4.4 times of water gaging dissolving after, filter, filtrate adds ethanol makes it contain the alcohol amount for 70%-80%, leaves standstill, and filters, reclaim filtrate, with precipitate dried under reduced pressure, get dry extract, pulverize again, sieve and obtain 80-120 purpose fine drug powder; (2) Margarita is cleaned earlier, eluriates, drains after, then with soak with ethanol, pulverize, be screened into middle powder, again water fly to pulverize, dry, be screened into fine powder; (3) with Radix Notoginseng, Folium Isatidis and Rhizoma Paridis through pulverizing, making solvent with ethanol after moistening, flood after 23.5-24.5 hour percolation, collect percolate, percolate is added the fine powder of the above-mentioned Margarita that makes, mixing after being evaporated to relative density 1.28-1.30 under 38 ℃-42 ℃, get extractum, drying under reduced pressure gets dry extract again, gets 80-120 purpose fine drug powder after pulverizing, sieving, add the 80-120 order fine drug powder that the Radix Astragali makes again, mixing incapsulates, promptly.
4. the precious capsular preparation method of stilbene according to claim 3, it is characterized in that described Radix Astragali decocting boiled 2 hours for the first time, 1 hour for the second time, collecting decoction, filter after, filtrate is evaporated to relative density 1.08-1.10 under 50 ℃, add 95% ethanol and make that to contain the alcohol amount be 70%, leave standstill, filter, filtrate reclaimed, in precipitate, add 4 times of water dissolutioies after, filter, filtrate adds 95% ethanol makes that to contain alcohol amount be 75%, leaves standstill, and filters, reclaim filtrate, with precipitate dried under reduced pressure, dry extract, pulverize again, sieving obtains 100 purpose fine drug powders.
5. the precious capsular preparation method of stilbene according to claim 3 is characterized in that described Radix Notoginseng, Folium Isatidis and Rhizoma Paridis are through pulverizing, moistening, in the percolator of evenly packing into, make solvent with 65% ethanol, flood after 24 hours percolation, collect percolate, percolate is evaporated to relative density 1.28-1.30 under 40 ℃, the back adds the fine powder of Margarita, mixing, get extractum, drying under reduced pressure gets dry extract again, gets 100 purpose fine drug powders after pulverizing, sieving.
6. the precious capsular preparation method of stilbene according to claim 3, after it is characterized in that described Margarita cleans, eluriates, drains, use 75% soak with ethanol, pulverize, be screened into powder in the 50-90 purpose, again water fly to pulverize, dry, be screened into the fine powder of 100-140 purpose.
7. the precious capsular preparation method of stilbene according to claim 6, the granularity that it is characterized in that powder in the described Margarita is 70 orders.
8. the precious capsular preparation method of stilbene according to claim 6 is characterized in that the granularity of the fine powder of described Margarita is 120 orders.
9. the precious capsular preparation method of stilbene according to claim 8, it is characterized in that described granularity be the fine powder of 120 purpose Margaritas be by middle powder water fly to pulverize, dry, sieve after, sterilize again, weigh, the qualified back of quality inspection becomes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021109486A CN1150934C (en) | 2002-03-04 | 2002-03-04 | Qizhen capsule and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021109486A CN1150934C (en) | 2002-03-04 | 2002-03-04 | Qizhen capsule and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1376497A true CN1376497A (en) | 2002-10-30 |
| CN1150934C CN1150934C (en) | 2004-05-26 |
Family
ID=4741334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021109486A Expired - Lifetime CN1150934C (en) | 2002-03-04 | 2002-03-04 | Qizhen capsule and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1150934C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105902772A (en) * | 2016-05-19 | 2016-08-31 | 宁波大昌药业有限公司 | Process for purifying effective ingredient of paris polyphylla, pseudo-ginseng and folium isatidis extract |
| CN108635493A (en) * | 2018-08-16 | 2018-10-12 | 马贵周 | Antitumor and cirsoid pharmaceutical composition for the treatment of and its preparation method and application |
| CN112755109A (en) * | 2020-11-25 | 2021-05-07 | 浙大宁波理工学院 | Preparation method for improving polysaccharide content in Qizhen capsule |
| CN112755110A (en) * | 2020-11-25 | 2021-05-07 | 浙大宁波理工学院 | Preparation method for improving content of saponins in Qizhen capsule |
-
2002
- 2002-03-04 CN CNB021109486A patent/CN1150934C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105902772A (en) * | 2016-05-19 | 2016-08-31 | 宁波大昌药业有限公司 | Process for purifying effective ingredient of paris polyphylla, pseudo-ginseng and folium isatidis extract |
| CN105902772B (en) * | 2016-05-19 | 2021-06-29 | 宁波大昌药业有限公司 | Process for purifying effective components of paris polyphylla, pseudo-ginseng and isatis leaf extract |
| CN108635493A (en) * | 2018-08-16 | 2018-10-12 | 马贵周 | Antitumor and cirsoid pharmaceutical composition for the treatment of and its preparation method and application |
| CN112755109A (en) * | 2020-11-25 | 2021-05-07 | 浙大宁波理工学院 | Preparation method for improving polysaccharide content in Qizhen capsule |
| CN112755110A (en) * | 2020-11-25 | 2021-05-07 | 浙大宁波理工学院 | Preparation method for improving content of saponins in Qizhen capsule |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1150934C (en) | 2004-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563B (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN101181529B (en) | Chinese medicine composition for curing tumor and preparation method thereof | |
| CN101869667B (en) | Chinese herbal medicinal composition for treating lung cancer | |
| CN101125178A (en) | Traditional Chinese medicine for treating tumor | |
| CN103550506B (en) | A kind of in radiotherapy with the use of Chinese medicine composition | |
| CN102688317B (en) | Traditional Chinese medicine for treating liver cancer | |
| CN1150934C (en) | Qizhen capsule and its preparing process | |
| CN110339276B (en) | Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof | |
| CN102247479A (en) | Antitumor strong medicine and preparation method thereof | |
| CN101564464B (en) | Chinese medicament for adjusting organism immunity of tumor patients | |
| CN101007159B (en) | Traditional Chinese medicine for preventing and controlling tumor | |
| CN101007052B (en) | An antitumor medicine and its preparation method | |
| CN103417911A (en) | Traditional Chinese medicine composition for supporting chemo-treatment | |
| CN104258260B (en) | A kind of saline cistanche alcohol extracting thing, preparation method and its usage | |
| CN103690832A (en) | Traditional Chinese medicinal composition for treating viral myocarditis | |
| CN103656469A (en) | Compound cantharides traditional Chinese medicine composition and use of preparation thereof in preparation of medicine for treating radiation-induced pulmonary injury | |
| CN112717097A (en) | Traditional Chinese medicine composition for treating gastric cancer and preparation method thereof | |
| CN103977276A (en) | Traditional Chinese medicine capsule used for treating radiocystitis | |
| CN102949679A (en) | Medicine for curing lung cancer and preparation method thereof | |
| CN115531488B (en) | Composition for soothing liver and strengthening spleen and being used for postoperative adjuvant therapy of breast cancer and preparation method thereof | |
| CN114588240B (en) | Traditional Chinese medicine composition for treating colorectal cancer and preparation method and application thereof | |
| CN101530589B (en) | Chinese medicinal preparation for treating cancers | |
| CN100348249C (en) | Method for preparing medicine for treating malignancy disease and use thereof | |
| CN102302718B (en) | Antitumor medicinal composition and preparation method thereof | |
| CN1318073C (en) | Chinese medicine compound preparation for treating lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NINGBO DACHANG MEDICINE CO., LTD. Free format text: FORMER OWNER: WANG GUICHANG Effective date: 20090731 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090731 Address after: Zhejiang province Fenghua City Xikou Zhen Feng Tong Road No. 500 Patentee after: NINGBO DACHANG PHARMACEUTICAL CO., LTD. Address before: Zhejiang province Fenghua City Xikou Zhen Feng Tong Road No. 500 Ningbo Dachang Pharmaceutical Co. Ltd. Patentee before: Wang Guichang |
|
| CX01 | Expiry of patent term |
Granted publication date: 20040526 |
|
| CX01 | Expiry of patent term |